Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more


What is Cholangiocarcinoma?

Cholangiocarcinoma is cancer of the bile ducts, which transfer bile from the liver to the small intestines.


Cholangiocarcinoma is cancer of the bile ducts, which transfer bile from the liver to the small intestines.
Acknowledgement of Cholangiocarcinoma has not been added yet.
Synonyms for Cholangiocarcinoma has not been added yet.
Cause of Cholangiocarcinoma has not been added yet.
Symptoms include weight loss, itching, abdominal pain, fever and jaundice (yellowing of the skin and eyes).
Cholangiocarcinoma may be diagnosed through a combination of imaging, blood tests and endoscopy.
Diagnostic tests of Cholangiocarcinoma has not been added yet
Surgery currently the only treatment; however, chemotherapy and radiation therapy may be used after surgery to decrease the chances of reoccurrence.
Prognosis of Cholangiocarcinoma has not been added yet.
Tips or Suggestions of Cholangiocarcinoma has not been added yet.
References of Cholangiocarcinoma has not been added yet.
Community External News Link
Title Date Link
FDA Approves Orphan Drug Pemigatinib for Rare Bile Duct Cancer Cholangiocarcinoma 06/10/2020
Community Resources
Title Description Date Link

Clinical Trials

Cords registry

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.

Enrolling is easy.

  1. Complete the screening form.
  2. Review the informed consent.
  3. Answer the permission and data sharing questions.

After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.

Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.

Visit to enroll.

Community Leaders


Expert Questions

Ask a question

Community User List

Husband has cholangiocarcinoma
My father was diagnosed with bile duct cancer October 2007. He has undergone removal of 3/4 of his liver, radiation and chemo. Today, we found out he has 3 nodules in his lungs where the Klatskin...

Start a Community

Don't See Your Condition On Rareshare?

Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.


Have questions about rareshare?

Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.


Our Communities

Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.


Our Resources

Our rare disease resources include e-books and podcasts





Our Community Leaders

Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.